Alnylam Pharmaceuticals Inc (ALNY)
ALNY Down Despite Positive Data From Heart Disease Drug Study
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Friday, Alnylam Pharmaceuticals Inc. ALNY stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM). Topline data was revealed in June.
Alnylam shares slide after heart drug data fails to impress investors
Alnylam Pharmaceuticals' shares fell nearly 11% before the bell on Friday, after data for its closely watched heart drug fell short of heightened investor expectations.
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
The 3 Best Gene Editing Stocks to Buy in August 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Christine Lindenboom - SVP, IR and Corporate Communications Yvonne Greenstreet - CEO Tolga Tanguler - CCO Pushkal Garg - CMO Jeff Poulton - CFO Conference Call Participants Tazeen Ahmad - Bank of America Maury Raycroft - Jefferies Julian Pino - Stifel Kostas Biliouris - BMO Capital Markets Jessica Fye - JPMorgan David Lebowitz - Citi Gena Wang - Barclays Ritu Baral - TD Cowen Mike Ulz - Morgan Stanley William Pickering - Bernstein Myles Minter - William Blair Luca Issi - RBC Capital Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Second Quarter 2024 Conference Call.
Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $0.74 per share. This compares to loss of $2.21 per share a year ago.
Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Stock Is a Blockbuster Biopharma In the Making
Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ: ALNY ) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has several drugs already on the market, the biopharma is not yet profitable.
